Forum Alert: BioSante Pharmaceuticals, Inc. will Present at the Informed Investors Biotechnology & Healthcare Investor Forum at The Hyatt Regency in San Francisco on Wednesday, December 7, 2005, 10:50 am PST.LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (AMEX AMEX
See: American Stock Exchange : BPA BPA British Paediatric Association. ) will present at the following forum:
What: Informed Investors Biotechnology & Healthcare Investor Forum in San Francisco
When: December 7, 2005 @ 10:50 AM Pacific Standard Time
Sponsors: Barron's, The Wall Street Journal and Business Wire
Keynote Presentations: John McCamant, Editor of The Medical Technology Stock Letter, Adam Noah, Ph.D., Vice President, Biotechnology Equity Research, Merriman Curhan Ford & Co.
Forum Highlights Include: Networking session and Industry Panel Discussion at the conclusion of the presentations
Where: The Hyatt Regency Hotel, 5 Embarcadero Center, San Francisco, CA 94111
How to attend: Pre-registration is necessary. To register, contact Cary Loeser, email@example.com, or 804-327-3407. You may also call Customer Service at 888-301-6618, or register at the following link: http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp
If you are unable to attend the live event, the forum will be archived and available via webcast at http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp
Contact: Phillip Donenberg, Chief Financial Officer, firstname.lastname@example.org , (847)478-0500
BioSante is developing a pipeline of hormone therapy Hormone therapy
Treating cancers by changing the hormone balance of the body, instead of by using cell-killing drugs.
Mentioned in: Breast Cancer, Thyroid Cancer
hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel(TM) (bioidentical testosterone gel) for the treatment of female sexual dysfunction sexual dysfunction
Inability to experience arousal or achieve sexual satisfaction under ordinary circumstances, as a result of psychological or physiological problems. (FSD FSD Female Sexual Dysfunction
FSD File System Driver
FSD Family Support Division
FSD Fire Services Department (Hong Kong)
FSD Full Scale Development
FSD Full Scale Deflection
FSD Federal Systems Division ). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax anthrax (ăn`thrăks), acute infectious disease of animals that can be secondarily transmitted to humans. It is caused by a bacterium (Bacillus anthracis and ricin ricin /ri·cin/ (ri´sin) a phytotoxin in the seeds of the castor oil plant (Ricinus communis), used in the synthesis of immunotoxins.
n. , and drug delivery systems.